PATIENTS & CARE PARTNERS Putting patients and their families first
We are rethinking care and how it is delivered to help patients and families impacted by brain health disorders.
News The latest from Sage
press releases & statements
events & presentations
Pipeline
Compound
Target Indications
Phase 1
Phase 2
Phase 3
Status
Postpartum Depression Commercial Products
ZURZUVAE®*
(zuranolone) CIV
(zuranolone) CIV
- Postpartum Depression
Marketed
Marketed
Programs In Evaluation
-
SAGE-324**GABA Hypofunction
-
SAGE-689Acute GABA Hypofunction
-
SAGE-421NMDA Hypofunction
-
SAGE-319GABA Hypofunction
*Collaboration Partners: Biogen Inc. and Shionogi for zuranolone
**In July 2024, we announced discontinuation of clinical development of SAGE-324 in ET. Sage
is
evaluating next steps, if any, for other potential indications.
Please refer to the
U.S.
Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established.
We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our
Privacy Policy
and
Terms of Use
.